Aclaris Therapeutics (ACRS) Share-based Compensation (2014 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Share-based Compensation of $19.7 million for Q1 2026, up 7063.64% year-over-year from $275000.0 in Q1 2025, and up 573.27% quarter-over-quarter from $2.9 million in Q4 2025.
Aclaris Therapeutics (ACRS) Share-based Compensation (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Share-based Compensation history runs 13 years deep, the most recent figure standing at $19.7 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 7063.64% year-over-year to $19.7 million; the TTM figure through Mar 2026 stood at $19.7 million (up 243.86% YoY), while the FY2025 annual figure was $12.4 million, up 23.84% from the prior year.
- Share-based Compensation for Q1 2026 stood at $19.7 million, up from $2.9 million in the prior quarter.
- The five-year high for Share-based Compensation was $19.7 million in Q1 2026, with the low at -$19.3 million in Q4 2023.
- The 5-year median for Share-based Compensation is $3.0 million (2024), against an average of $3.7 million.
- The sharpest annual moves came in 2023 and 2026: Share-based Compensation plunged 500.66% in 2023, then jumped 7063.64% in 2026.
- Aclaris Therapeutics' Share-based Compensation stood at $4.8 million in 2022, then slumped by 500.66% to -$19.3 million in 2023, then jumped by 97.65% to -$453000.0 in 2024, then soared by 745.92% to $2.9 million in 2025, then jumped by 573.27% to $19.7 million in 2026.
- Business Quant data shows ACRS's Share-based Compensation at $19.7 million in Q1 2026, $2.9 million in Q4 2025, and $2.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | 18.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.00 Mn |
| Jun 30, 2026 | 18.00 Mn |
| Mar 31, 2026 | 19.70 Mn |
| Mar 31, 2026 | 19.70 Mn |
| Dec 31, 2025 | 2.93 Mn |
| Dec 31, 2025 | 2.93 Mn |
| Sep 30, 2025 | 2.86 Mn |
| Sep 30, 2025 | 2.86 Mn |
| Jun 30, 2025 | 14.00 Mn |
| Jun 30, 2025 | 14.00 Mn |
| Mar 31, 2025 | 275,000.00 |
| Mar 31, 2025 | 275,000.00 |
| Dec 31, 2024 | -453,000.00 |
| Dec 31, 2024 | -453,000.00 |
| Sep 30, 2024 | 3.00 Mn |
| Sep 30, 2024 | 3.00 Mn |
| Jun 30, 2024 | 2.90 Mn |
| Jun 30, 2024 | 2.90 Mn |
| Mar 31, 2024 | 2.09 Mn |
| Mar 31, 2024 | 2.09 Mn |